Coty Q1 Beat Not Enough to Alter Wait Stance

What happened

Coty reported first-quarter fiscal 2027 revenue and adjusted earnings ahead of expectations, but management stressed the company remains in a transition year focused on improving consumer demand, margins, and market share. In the latest 10-Q (quarter ended September 2026), revenues declined 6% year-over-year to $1.58 billion, with Prestige down 4% and Consumer Beauty down 9%, though the earnings call suggests Q1 FY27 performed better than analysts' estimates. The master report's judgment is WAIT, citing high leverage (net debt/EBITDA 4.2x, interest coverage 1.1x), a GAAP net loss in FY25, and structural losses in Consumer Beauty. While the beat is encouraging, it does not yet resolve the core challenges of deleveraging and segment profitability, and the company's DCF estimate of $4.35 still implies upside but without margin of safety. Given the speculative turnaround nature and ongoing execution risks, we maintain a WAIT stance.

Implication

Investors should remain cautious despite the earnings beat, as the company still faces high leverage, weak Consumer Beauty, and tariff headwinds. The beat may indicate early progress in stabilizing demand, but one quarter does not confirm a trend. Key catalysts to watch include prestige fragrance sell-out conversion to reported revenue, outcomes of the Consumer Beauty strategic review, and deleveraging progress (net debt/EBITDA toward 3x and interest coverage above 2x). Until these milestones are met, the risk/reward remains unattractive relative to the balance sheet volatility. A disciplined approach would be to hold or wait for a better entry if the thesis strengthens.

Thesis delta

No change to the WAIT judgment. The earnings beat is a modest positive but does not alter the high-risk profile. We need consistent evidence of margin recovery and deleveraging before upgrading.